Skin care management in cancer patients: An evaluation of quality of life and tolerability

Supportive Care in Cancer

Volumn 19, Issue 4, 2011, Pages 545-554

  Haley, Ann Cameron ^a   Calahan, Cara ^a   Gandhi, Mona ^a   West, Dennis P ^a   Rademaker, Alfred ^a   Lacouture, Mario E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer; Chemotherapy; Dry skin; HFSR; Radiation therapy; Skin care; Skin irrations

Indexed keywords

DERMATOLOGICAL AGENT;

ACNE; ADVERSE OUTCOME; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; DERMATITIS; DRUG TOLERABILITY; DRY SKIN; FACE ERYTHEMA; FEMALE; FOLLOW UP; HAND FOOT SKIN RACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; ROSACEA; SCORING SYSTEM; SELF REPORT; SKIN CARE; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN TOXICITY; SKINDEX 16 QUESTIONNAIRE;

EMOLLIENTS; FACE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASMS; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SKIN CARE; SKIN DISEASES; SOAPS;

EID: 79953654283     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0851-8     Document Type: Article

References (21)

1. Lacouture M, West D, Tigue C, Knox K, Bennett C (2008) Cutaneous toxicities of targeted cancer therapies. Community Oncology 5(7):413-414
2. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. Support Care Cancer 16(3):267-273 (Pubitemid 351422803)
3. O'Keeffe P, Parrilli M, Lacouture M (2006) Toxicity of targeted therapy: focus on rash and other dermatologic side effects. Oncol Nurses Ed 20:1-6
4. Wagner L, Lacouture M (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21(11 Suppl 5):34-36
5. Gandhi M, Oishi K, Zubal B. Unanticipated toxicities from anticancer therapies: survivors' perspectives.Support Care in Cancer (in press)
6. Autier J, Escudier B, Wechsler J, Spatz A, Robert C (2008) Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 144(7):886-892 (Pubitemid 352039741)
7. Richardson L, Wang W, Hartzema A, Wagner S (2007) The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J 13(6):581-587 (Pubitemid 350045708)
8. Susser W, Whitaker-Worth D, Grant-Kels J (1999) Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40(3):367-398, quiz 99-400
9. Lynch T, Kim E, Eaby B, Garey J, West D, Lacouture M (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610-621 (Pubitemid 350012125)
10. McQuestion M (2006) Evidence-based skin care management in radiation therapy. Semin Oncol Nurs 22(3):163-173
11. Bolderston A, Lloyd N, Wong R, Holden L, Robb-Blenderman L (2006) The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 14(8):802-817 (Pubitemid 44060993)
12. Lindi® Skin (2008) http://lindiskin.com/
13. CTC v2.0 and common terminology criteria for adverse events v3.0 (CTCAE). (2009) http://ctep.cancer.gov/reporting/index.html
14. Chren M, Lasek R, Sahay A, Sand L (2001) Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 5(2):105-110 (Pubitemid 32588315)
15. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris M et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903-909 (Pubitemid 44615944)
16. Weber T, Ceilley R, Buerger A, Kolbe L, Trookman N, Rizer R et al (2006) Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol 5(3):227-232 (Pubitemid 44314384)
17. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491-500 (Pubitemid 40903630)
18. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T et al (2010) Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 102(1):47-53
19. Fairclough D, Fetting J, Cella D, Wonson W, Moinpour C (1999) Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8(8):723-731 (Pubitemid 30331120)
20. Frith H, Harcourt D, Fussell A (2007) Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer. Eur J Oncol Nurs 11(5):385-391
21. Burish T, Snyder S, Jenkins R (1991) Preparing patients for cancer chemotherapy: effect of coping preparation and relaxation interventions. J Consult Clin Psychol 59(4):518-525